Shares of Kadmon Holdings Inc (NYSE:KDMN) have been given an average recommendation of “Buy” by the six analysts that are covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $13.23.
A number of equities research analysts recently issued reports on KDMN shares. HC Wainwright set a $25.00 price target on Kadmon and gave the stock a “buy” rating in a research report on Monday, August 13th. Zacks Investment Research raised Kadmon from a “hold” rating to a “buy” rating and set a $4.25 price target on the stock in a research report on Wednesday, July 11th. Finally, WBB Securities upgraded Kadmon from a “sell” rating to a “hold” rating and set a $2.90 target price for the company in a research note on Wednesday.
Shares of Kadmon stock traded down $0.05 on Wednesday, hitting $2.84. The stock had a trading volume of 37,564 shares, compared to its average volume of 815,253. Kadmon has a twelve month low of $2.62 and a twelve month high of $5.86. The company has a market capitalization of $377.76 million, a price-to-earnings ratio of -2.04 and a beta of 3.65.
Institutional investors and hedge funds have recently made changes to their positions in the company. MetLife Investment Advisors LLC bought a new position in shares of Kadmon in the 2nd quarter valued at $148,000. Rhumbline Advisers bought a new position in Kadmon during the 2nd quarter worth $256,000. Acuta Capital Partners LLC raised its position in Kadmon by 52.3% during the 2nd quarter. Acuta Capital Partners LLC now owns 9,060,014 shares of the company’s stock worth $36,149,000 after purchasing an additional 3,110,014 shares during the last quarter. Metropolitan Life Insurance Co. NY bought a new position in Kadmon during the 2nd quarter worth $105,000. Finally, Vivo Capital LLC raised its position in Kadmon by 213.6% during the 2nd quarter. Vivo Capital LLC now owns 10,454,545 shares of the company’s stock worth $68,919,000 after purchasing an additional 7,121,212 shares during the last quarter. Institutional investors own 69.66% of the company’s stock.
Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease.
Read More: Penny Stocks, Risk and Reward Factors
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.